{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/rheumatoid-arthritis/how-up-to-date-is-this-topic/update/","result":{"pageContext":{"chapter":{"id":"add57644-4b68-5377-b8ce-b0cc395570f0","slug":"update","fullItemName":"Update","depth":2,"htmlHeader":"<!-- begin field 7415b736-7114-47f2-9e89-d50024fbe19e --><h2>Update</h2><!-- end field 7415b736-7114-47f2-9e89-d50024fbe19e -->","summary":null,"htmlStringContent":"<!-- begin item 5ac0d617-1e6e-45b4-a915-e59589d838e7 --><!-- end item 5ac0d617-1e6e-45b4-a915-e59589d838e7 -->","topic":{"id":"80425c66-11ed-5a54-aecf-455f339cb0cd","topicId":"d9596563-d663-48ca-8d6a-4ddeb263b46e","topicName":"Rheumatoid arthritis","slug":"rheumatoid-arthritis","lastRevised":"Last revised in April 2020","chapters":[{"id":"e5b4cb7c-c830-59e0-a369-a8151bd28e7c","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"28d53d37-f5b2-5ab0-bd6f-6c6858fc63e4","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"8eb76d85-83a8-5bb1-be89-15a9e86def8d","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"7eba8b39-2fb0-52b0-8988-5d108c1720fa","slug":"changes","fullItemName":"Changes"},{"id":"add57644-4b68-5377-b8ce-b0cc395570f0","slug":"update","fullItemName":"Update"}]},{"id":"62d68b4b-4522-5afb-88fe-48b87fc31a2d","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f9fe7005-bf48-5a4e-bc7c-08550e792a18","slug":"goals","fullItemName":"Goals"},{"id":"cc0b2b43-25e2-5936-ad94-217419fd0126","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6a0fead6-ca32-5399-9b1b-22b31fc0c765","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f76001a5-99f4-5086-bc05-c1cd7535aab0","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"fb29501f-d465-5652-b659-ffb4e5c8e928","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"3181265d-dee9-5587-974d-b4bae95c10ee","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"167941e5-411a-5afd-94af-8e7725b24b1a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"bb48f4e9-23c4-5828-bccb-666f4dbc512d","slug":"definition","fullItemName":"Definition"},{"id":"06cc7595-3f6c-59d6-929b-964159afde4d","slug":"prevalence-incidence","fullItemName":"Prevalence and incidence"},{"id":"8fb1fc93-039a-5d6b-a86d-aeb61578f11d","slug":"complications","fullItemName":"Complications"}]},{"id":"e352008d-7a0c-55ba-b778-c6218ef4ef69","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"b9d257ab-0ebb-52bf-908a-8ebebe6c550c","slug":"when-to-suspect-ra","fullItemName":"When to suspect RA"},{"id":"25d80dc3-ea8a-5560-8a0b-3a64b87c5690","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"5de822df-3081-5ed6-a21b-e3e2925436bd","slug":"investigations-for-suspected-ra","fullItemName":"Investigations for suspected RA"}]},{"id":"6f1e7941-f462-5d64-8822-8328310b81b9","fullItemName":"Management","slug":"management","subChapters":[{"id":"2ed609a5-1052-56f5-b263-63d4e5325949","slug":"suspected-ra","fullItemName":"Scenario: Suspected RA"},{"id":"0ba5ec6e-3f0f-5157-8e24-55ef24b2cfe9","slug":"confirmed-ra","fullItemName":"Scenario: Confirmed RA"},{"id":"c490cb4d-f228-5c81-b9f2-0ac419b6d60a","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"13cb1ed1-b962-5e8a-88c8-8b7185af06df","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"e875cc8d-258b-5535-9d34-40f03cb150c7","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"9b45cf27-1cfb-591d-a936-5e49910f88ac","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"93bd3cb0-31a7-5acf-bc5f-8858b54e466b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"a24a6436-a685-5277-8c22-524ebe895154","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4258a438-16bd-591d-bd95-5d6a682e1696","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"58298e48-e237-5259-b79b-da11e96f0a4e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"6c1abdea-39c1-5537-8e4f-6e6ff3a71736","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"8eb76d85-83a8-5bb1-be89-15a9e86def8d","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"4fcebb84-f7de-5eb1-8456-77b99e31b6cc","slug":"new-evidence","fullItemName":"New evidence","depth":3,"htmlHeader":"<!-- begin field ced002d7-a96d-44a3-9654-da97c9cd235a --><h3>New evidence</h3><!-- end field ced002d7-a96d-44a3-9654-da97c9cd235a -->","summary":null,"htmlStringContent":"<!-- begin item 97db4c80-4768-440e-a41f-8a9301d38101 --><!-- begin field fbb98162-0e0b-40cf-a8e4-ecaa2c7ec955 --><h3>Evidence-based guidelines</h3><!-- end field fbb98162-0e0b-40cf-a8e4-ecaa2c7ec955 --><!-- begin field c5dd3bbe-7739-4e43-8777-daa6da52d681 --><p>No new evidence-based guidelines since 1 December 2018.</p><!-- end field c5dd3bbe-7739-4e43-8777-daa6da52d681 --><!-- begin field 2931b55e-cbb5-4055-97a2-82263f7c9f53 --><h3>HTAs (Health Technology Assessments)</h3><!-- end field 2931b55e-cbb5-4055-97a2-82263f7c9f53 --><!-- begin field 13e88c9d-0755-4ce8-8e5a-b1ec892e57ca --><p>No new HTAs since 1 December 2018.</p><!-- end field 13e88c9d-0755-4ce8-8e5a-b1ec892e57ca --><!-- begin field c427e72a-d69f-4bde-8ec4-b0bca669fdc1 --><h3>Economic appraisals</h3><!-- end field c427e72a-d69f-4bde-8ec4-b0bca669fdc1 --><!-- begin field 1cad4968-9405-4345-ab46-12161aeb8351 --><p>No new economic appraisals since 1 December 2018.</p><!-- end field 1cad4968-9405-4345-ab46-12161aeb8351 --><!-- begin field d192ad21-03ae-4d44-9eee-2685bf446bdc --><h3>Systematic reviews and meta-analyses</h3><!-- end field d192ad21-03ae-4d44-9eee-2685bf446bdc --><!-- begin field bc6ab313-e7e1-4fa2-9752-6caf6be45bea --><ul><li>Sepriano, A., Kerschbaumer, A., Smolen, J.S. et al. (2020) <em>Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis.</em> Annals of the Rheumatic Diseases. <a href=\"https://ard.bmj.com/\" data-hyperlink-id=\"c49ae8b5-e1e6-4b99-a855-ab7300adf03d\">www.ard.bmj.com</a> [<a href=\"https://ard.bmj.com/content/early/2020/02/07/annrheumdis-2019-216653\" data-hyperlink-id=\"8ddd27ff-b593-49b0-a528-ab7300adf056\">Free Full-Text</a>]</li><li>Kerschbaumer, A., Sepriano, A., Smolen, J.S. et al. (2020) <em>Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing 2019 update of the EULAR recommendations for management of rheumatoid arthritis.</em> Annals of Rheumatic Diseases. <a href=\"https://ard.bmj.com/\" data-hyperlink-id=\"bfb33164-9775-4db9-b8f5-ab7300adf060\">www.ard.bmj.com</a> [<a href=\"https://ard.bmj.com/content/early/2020/02/17/annrheumdis-2019-216656\" data-hyperlink-id=\"4bcac8a5-5d77-48a1-ab6b-ab7300adf069\">Free Full-Text</a>]</li><li>Smolen, J.S., Landewe, R.B., Bijlsma, J.W. et al. (2020).<em> EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.</em> Annals of Rheumatic Diseases. <a href=\"https://ard.bmj.com/\" data-hyperlink-id=\"9bf0893a-38af-47bc-bb3e-ab7300adf076\">www.ard.bmj.com</a> [<a href=\"https://ard.bmj.com/content/early/2020/01/22/annrheumdis-2019-216655.long\" data-hyperlink-id=\"3f8f13aa-0264-4f2a-abac-ab7300adf07f\">Free Full-Text</a>]</li></ul><!-- end field bc6ab313-e7e1-4fa2-9752-6caf6be45bea --><!-- begin field 6e1d07d3-f274-4ee2-84ca-78f2c8028f94 --><h3>Primary evidence</h3><!-- end field 6e1d07d3-f274-4ee2-84ca-78f2c8028f94 --><!-- begin field 7ca2b200-45cb-40a0-93e0-b0a7a5f4db21 --><p>No new randomized controlled trials since 1 December 2018.</p><!-- end field 7ca2b200-45cb-40a0-93e0-b0a7a5f4db21 --><!-- end item 97db4c80-4768-440e-a41f-8a9301d38101 -->","subChapters":[]},{"id":"9d3ba05c-4e27-539f-9b22-61aef5845953","slug":"new-policies","fullItemName":"New policies","depth":3,"htmlHeader":"<!-- begin field 06591777-91c6-4151-8d5f-46efd1642a75 --><h3>New policies</h3><!-- end field 06591777-91c6-4151-8d5f-46efd1642a75 -->","summary":null,"htmlStringContent":"<!-- begin item 45f86581-5b1c-4e80-a148-19ded4ba2b77 --><!-- begin field f911677d-291d-47b5-a6af-9e6d03a3c1c1 --><p>No new national policies or guidelines since 1 December 2018.</p><!-- end field f911677d-291d-47b5-a6af-9e6d03a3c1c1 --><!-- end item 45f86581-5b1c-4e80-a148-19ded4ba2b77 -->","subChapters":[]},{"id":"295684aa-7448-55c7-a1d4-af6feef0ffda","slug":"new-safety-alerts","fullItemName":"New safety alerts","depth":3,"htmlHeader":"<!-- begin field 9438b76a-4302-47bc-b48a-fc53fecf0c9d --><h3>New safety alerts</h3><!-- end field 9438b76a-4302-47bc-b48a-fc53fecf0c9d -->","summary":null,"htmlStringContent":"<!-- begin item a01b71a2-e4e2-44ea-a6f5-9b5fa8221cbc --><!-- begin field 4e921f7d-5350-46b7-ae75-d145f087853c --><p>No new safety alerts since 1 December 2018.</p><!-- end field 4e921f7d-5350-46b7-ae75-d145f087853c --><!-- end item a01b71a2-e4e2-44ea-a6f5-9b5fa8221cbc -->","subChapters":[]},{"id":"26587f84-ead6-5e3d-89d9-b086db3e12a5","slug":"changes-in-product-availability","fullItemName":"Changes in product availability","depth":3,"htmlHeader":"<!-- begin field b82efbff-c877-4a9f-b631-ab5d9384b4f0 --><h3>Changes in product availability</h3><!-- end field b82efbff-c877-4a9f-b631-ab5d9384b4f0 -->","summary":null,"htmlStringContent":"<!-- begin item dbba7c16-f4c7-42ad-9df6-194c6c4d77d2 --><!-- begin field 712b2336-b198-4449-ae69-1a93269b26cd --><ul><li>Committee for Medicinal Products for Human Use (CHMP) recommends approval of upadacitinib (Rinvoq) for rheumatoid arthritis. See more <a href=\"https://www.ema.europa.eu/en/medicines/human/summaries-opinion/rinvoq\" data-hyperlink-id=\"bfdc8da0-1f4e-43a1-805e-aaf100a15733\">here</a>.</li><li>The first subcutaneous formulation of infliximab has been licensed for treatment of rheumatoid arthritis. See more <a href=\"http://www.pharmatimes.com/news/subcutaneous_remsima_launched_in_uk_1327629\" data-hyperlink-id=\"bc3966c4-410f-42a5-9921-ab7600f2a619\">here</a>.</li><li>Filgotinib is licensed for the treatment of moderate to severe active rheumatoid arthritis in adults who have responded inadequately to, or who are intolerant to one or more DMARDs. It may be used as a monotherapy or in combination with methotrexate. See more <a href=\"https://www.medicines.org.uk/emc/product/11809/smpc\" data-hyperlink-id=\"5421d8bf-1c9c-4b65-b6d2-ac4f00a276c9\">here</a>.</li></ul><!-- end field 712b2336-b198-4449-ae69-1a93269b26cd --><!-- end item dbba7c16-f4c7-42ad-9df6-194c6c4d77d2 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}